• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清叶酸受体α、间皮素和巨核细胞促进因子在卵巢癌中的表达:与疾病分期和分级的关系,并与 CA125 和 HE4 的比较。

Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4.

机构信息

Department of Diagnostics Development, Morphotek, Inc,, 210 Welsh Pool Road, Exton, PA, USA.

出版信息

J Ovarian Res. 2013 Apr 17;6(1):29. doi: 10.1186/1757-2215-6-29.

DOI:10.1186/1757-2215-6-29
PMID:23590973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3640997/
Abstract

BACKGROUND

Evaluate and compare the utility of serum folate receptor alpha (FRA) and megakaryocyte potentiating factor (MPF) determinations relative to serum CA125, mesothelin (MSLN) and HE4 for the diagnosis of epithelial ovarian cancer (EOC).

METHODS

Electrochemiluminescent assays were developed for FRA, MSLN and MPF and used to assess the levels of these biomarkers in 258 serum samples from ovarian cancer patients. Commercial assays for CA125 and HE4 were run on a subset of 176 of these samples representing the serous histology. Data was analyzed by histotype, stage and grade of disease. A comparison of the levels of the FRA, MSLN and MPF biomarkers in serum, plasma and urine was also performed in a subset of 57 patients.

RESULTS

Serum and plasma levels of FRA, MSLN and MPF were shown to be highly correlated between the two matrices. Correlations between all pairs of markers in 318 serum samples were calculated and demonstrated the highest correlation between HE4 and MPF, and the lowest between FRA and MPF. Serum levels of all markers showed a dependence on both stage and grade of disease. A multi-marker logistic regression model was developed resulting in an AUC=0.91 for diagnosis of serous ovarian cancer, a significant improvement over the AUC for any of the individual markers, including CA125 (AUC=0.84).

CONCLUSIONS

FRA has significant potential as a biomarker for ovarian cancer, both as a stand-alone marker and in combination with other known markers for EOC. The lack of correlation between the various markers analyzed in the present study suggests that a panel of markers can aid in the detection and/or monitoring of this disease.

摘要

背景

评估和比较血清叶酸受体α(FRA)和巨核细胞增强因子(MPF)与血清 CA125、间皮素(MSLN)和 HE4 测定在诊断上皮性卵巢癌(EOC)方面的效用。

方法

开发了电化学发光测定法用于 FRA、MSLN 和 MPF,并用于评估 258 份卵巢癌患者血清样本中这些生物标志物的水平。对其中 176 份代表浆液性组织学的样本进行了 CA125 和 HE4 的商业测定。通过疾病的组织类型、分期和分级对数据进行了分析。还在 57 名患者的亚组中比较了血清、血浆和尿液中 FRA、MSLN 和 MPF 生物标志物的水平。

结果

血清和血浆中的 FRA、MSLN 和 MPF 水平在两种基质之间显示出高度相关性。在 318 份血清样本中计算了所有标志物对之间的相关性,并显示 HE4 与 MPF 之间相关性最高,而 FRA 与 MPF 之间相关性最低。所有标志物的血清水平均依赖于疾病的分期和分级。建立了多标志物逻辑回归模型,用于诊断浆液性卵巢癌的 AUC=0.91,明显优于任何单个标志物(包括 CA125,AUC=0.84)的 AUC。

结论

FRA 作为卵巢癌的生物标志物具有重要的潜力,无论是作为独立标志物还是与其他已知的 EOC 标志物联合使用。本研究中分析的各种标志物之间缺乏相关性表明,一组标志物可以辅助检测和/或监测这种疾病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/d7b48e0a56f6/1757-2215-6-29-10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/781be3457481/1757-2215-6-29-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/987635f1c19e/1757-2215-6-29-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/3b39c87f7806/1757-2215-6-29-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/a4748c3577e9/1757-2215-6-29-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/3ca0b41086b4/1757-2215-6-29-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/0d639d707f37/1757-2215-6-29-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/a746cc03cf1b/1757-2215-6-29-7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/c82c8747bd29/1757-2215-6-29-8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/8f01f7f4640d/1757-2215-6-29-9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/d7b48e0a56f6/1757-2215-6-29-10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/781be3457481/1757-2215-6-29-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/987635f1c19e/1757-2215-6-29-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/3b39c87f7806/1757-2215-6-29-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/a4748c3577e9/1757-2215-6-29-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/3ca0b41086b4/1757-2215-6-29-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/0d639d707f37/1757-2215-6-29-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/a746cc03cf1b/1757-2215-6-29-7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/c82c8747bd29/1757-2215-6-29-8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/8f01f7f4640d/1757-2215-6-29-9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e31/3640997/d7b48e0a56f6/1757-2215-6-29-10.jpg

相似文献

1
Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4.血清叶酸受体α、间皮素和巨核细胞促进因子在卵巢癌中的表达:与疾病分期和分级的关系,并与 CA125 和 HE4 的比较。
J Ovarian Res. 2013 Apr 17;6(1):29. doi: 10.1186/1757-2215-6-29.
2
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.巨核细胞增强因子作为恶性胸膜间皮瘤的肿瘤标志物:与间皮素相比的评估
Lung Cancer. 2008 Oct;62(1):45-54. doi: 10.1016/j.lungcan.2008.02.012. Epub 2008 Apr 3.
3
Folate receptor alpha, mesothelin and megakaryocyte potentiating factor as potential serum markers of chronic kidney disease.叶酸受体α、间皮素和巨核细胞增强因子作为慢性肾脏病潜在的血清标志物。
Biomark Insights. 2014 May 25;9:29-37. doi: 10.4137/BMI.S15245. eCollection 2014.
4
HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection.人附睾蛋白4(HE4)和可溶性间皮素相关肽(SMRP):卵巢癌检测中的潜在新型生物标志物
Oncol Lett. 2012 Sep;4(3):385-389. doi: 10.3892/ol.2012.757. Epub 2012 Jun 13.
5
A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.一种用于早期检测高级别浆液性卵巢癌的新型多重生物标志物panel。
Gynecol Oncol. 2018 Jun;149(3):585-591. doi: 10.1016/j.ygyno.2018.03.050. Epub 2018 Mar 21.
6
Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.血清 HE4 作为一种有用的生物标志物,可用于区分卵巢癌与良性盆腔疾病。
Int J Gynecol Cancer. 2012 Jul;22(6):1000-5. doi: 10.1097/IGC.0b013e318249bee7.
7
Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.血清miR-193a-5p、HE4和CA125诊断模型提高上皮性卵巢癌的诊断效能。
Pathol Oncol Res. 2018 Oct;24(4):739-744. doi: 10.1007/s12253-018-0392-x. Epub 2018 Mar 8.
8
The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.sEGFR、CA125 和 HE4 联合检测对上皮性卵巢癌诊断的临床价值。
Eur Rev Med Pharmacol Sci. 2020 Jan;24(2):604-610. doi: 10.26355/eurrev_202001_20036.
9
Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.HE4 和 CA125 标志物在 I 型和 II 型上皮性卵巢癌中的诊断性能。
Gynecol Oncol. 2013 Oct;131(1):52-8. doi: 10.1016/j.ygyno.2013.07.094. Epub 2013 Jul 25.
10
A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.一种多重生物标志物检测方法提高了 HE4 和 CA125 在卵巢肿瘤患者中的诊断性能。
PLoS One. 2020 Oct 19;15(10):e0240418. doi: 10.1371/journal.pone.0240418. eCollection 2020.

引用本文的文献

1
Efficacy and Safety of Farletuzumab in Ovarian Cancer: A Systematic Review and Single-Arm Meta-Analysis.法乐图单抗治疗卵巢癌的疗效与安全性:一项系统评价与单臂荟萃分析
Cureus. 2024 Nov 12;16(11):e73503. doi: 10.7759/cureus.73503. eCollection 2024 Nov.
2
Folate Receptor Alpha-A Secret Weapon in Ovarian Cancer Treatment?叶酸受体α——卵巢癌治疗的秘密武器?
Int J Mol Sci. 2024 Nov 6;25(22):11927. doi: 10.3390/ijms252211927.
3
Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers.叶酸修饰壳聚糖纳米粒:新一代抗癌纳米载体。

本文引用的文献

1
Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease.叶酸受体α(FRA)在乳腺癌中的表达:一种新分子亚型的鉴定及其与三阴性疾病的关联
Springerplus. 2012 Sep 28;1:22. doi: 10.1186/2193-1801-1-22. eCollection 2012.
2
Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type.叶酸受体-α(FRA)在妇科恶性肿瘤中的表达及其与肿瘤类型的关系。
Int J Gynecol Pathol. 2013 May;32(3):258-68. doi: 10.1097/PGP.0b013e3182774562.
3
Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case--control study.
Mol Cancer. 2024 Oct 31;23(1):244. doi: 10.1186/s12943-024-02163-z.
4
New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment-a narrative review.聚焦靶向治疗的卵巢癌治疗新希望与前景——一篇叙述性综述
Front Pharmacol. 2024 Jun 14;15:1416555. doi: 10.3389/fphar.2024.1416555. eCollection 2024.
5
Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer.所选生物标志物及其组合在卵巢癌诊断中的敏感性和特异性。
Diagnostics (Basel). 2024 Apr 30;14(9):949. doi: 10.3390/diagnostics14090949.
6
Multi-omics analyses of glucose metabolic reprogramming in colorectal cancer.多组学分析结直肠癌中葡萄糖代谢重编程。
Front Immunol. 2023 Jul 5;14:1179699. doi: 10.3389/fimmu.2023.1179699. eCollection 2023.
7
Fallopian tubal histogenesis of ovarian endometriosis-A study of folate receptor-alpha expression.卵巢子宫内膜异位症的输卵管组织发生——叶酸受体-α表达的研究
Front Med (Lausanne). 2023 Mar 2;10:1138690. doi: 10.3389/fmed.2023.1138690. eCollection 2023.
8
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes.叶酸受体α在卵巢癌组织和患者血清中与疾病负担和治疗结果相关。
Br J Cancer. 2023 Jan;128(2):342-353. doi: 10.1038/s41416-022-02031-x. Epub 2022 Nov 19.
9
Identification of Candidate Therapeutic Target Genes and Profiling of Tumor-Infiltrating Immune Cells in Pancreatic Cancer via Integrated Transcriptomic Analysis.基于转录组整合分析鉴定胰腺癌候选治疗靶基因及肿瘤浸润免疫细胞特征。
Dis Markers. 2022 Aug 23;2022:3839480. doi: 10.1155/2022/3839480. eCollection 2022.
10
A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer.一种具有肿瘤选择性二价叶酸受体α结合臂的T细胞接合双特异性抗体,用于治疗卵巢癌。
Oncoimmunology. 2022 Aug 20;11(1):2113697. doi: 10.1080/2162402X.2022.2113697. eCollection 2022.
尿中人附睾分泌蛋白4(He4)浓度在卵巢癌诊断中的应用:一项病例对照研究。
Asian Pac J Cancer Prev. 2012;13(9):4695-8. doi: 10.7314/apjcp.2012.13.9.4695.
4
Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.叶酸偶联物 EC145(Vintafolide)治疗耐药实体瘤患者的 I 期研究。
J Clin Oncol. 2012 Nov 10;30(32):4011-6. doi: 10.1200/JCO.2011.41.4946. Epub 2012 Oct 1.
5
HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection.人附睾蛋白4(HE4)和可溶性间皮素相关肽(SMRP):卵巢癌检测中的潜在新型生物标志物
Oncol Lett. 2012 Sep;4(3):385-389. doi: 10.3892/ol.2012.757. Epub 2012 Jun 13.
6
Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.多中心试验 EC145 治疗叶酸受体阳性的晚期肺腺癌。
J Thorac Oncol. 2012 Oct;7(10):1618-21. doi: 10.1097/JTO.0b013e318267d051.
7
Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance.肺癌中叶酸受体α的表达:诊断及预后意义
Oncotarget. 2012 Apr;3(4):414-425. doi: 10.18632/oncotarget.519.
8
Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorption.尿中的间皮素水平受肾小球滤过和肾小管重吸收的影响。
Clin Lung Cancer. 2012 Nov;13(6):470-4. doi: 10.1016/j.cllc.2011.12.004. Epub 2012 Mar 2.
9
Characterization of the human folate receptor alpha via novel antibody-based probes.通过基于新型抗体的探针表征人叶酸受体α
Oncotarget. 2011 Dec;2(12):1227-43. doi: 10.18632/oncotarget.412.
10
Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.评估卵巢癌缓解标志物 HE4、MMP7 和间皮素,并与既定标志物 CA125 进行比较。
Gynecol Oncol. 2012 Apr;125(1):65-9. doi: 10.1016/j.ygyno.2011.11.050. Epub 2011 Dec 7.